Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma.

ABSTRACT: Drug resistance mechanisms in renal cell carcinoma (RCC) still remain elusive. Although most patients initially respond to targeted therapy, acquired resistance can still develop eventually. Most of the patients suffer from intrinsic (genetic) resistance as well, suggesting that there is substantial need to broaden our knowledge in the field of RCC genetics. As molecular abnormalities occur for various reasons, ranging from single nucleotide polymorphisms to large chromosomal defects, conducting whole-genome association studies using high-throughput techniques seems inevitable. In principle, data obtained via genome-wide research should be continued and performed on a large scale for the purposes of drug development and identification of biological pathways underlying cancerogenesis. Genet

SUBMITTER: Bielecka ZF 

PROVIDER: S-EPMC4110478 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature